Preclinical and clinical activity of DZD1516, a full blood–brain barrier-penetrant, highly selective HER2 inhibitor

[1] Loibl S(2017)HER2-positive breast cancer The Lancet 389 2415-2429

[2] Gianni L(2014)Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications Mol Biol Int 2014 852748-119

[3] Iqbal N(2012)Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N Engl J Med 366 109-1791

[4] Iqbal N(2012)Trastuzumab emtansine for HER2-positive advanced breast cancer N Engl J Med 367 1783-1154

[5] Baselga J(2022)Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer N Engl J Med 386 1143-2743

[6] Cortés J(2006)Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733-609

[7] Kim S-B(2020)Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial J Clin Oncol 38 3138-4843

[8] Im S-A(2020)Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer N Engl J Med 382 597-2441

[9] Hegg R(2011)Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER Clin Cancer Res 17 4834-904

[10] Im Y-H(2019)Central nervous system metastasis in patients with HER2-positive metastatic breast cancer: patient characteristics, treatment, and survival from SystHERs Clin Cancer Res 25 2433-1584

[1] Loibl S(2017)HER2-positive breast cancer The Lancet 389 2415-2429

[2] Gianni L(2014)Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications Mol Biol Int 2014 852748-119

[3] Iqbal N(2012)Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N Engl J Med 366 109-1791

[4] Iqbal N(2012)Trastuzumab emtansine for HER2-positive advanced breast cancer N Engl J Med 367 1783-1154

[5] Baselga J(2022)Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer N Engl J Med 386 1143-2743

[6] Cortés J(2006)Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733-609

[7] Kim S-B(2020)Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial J Clin Oncol 38 3138-4843

[8] Im S-A(2020)Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer N Engl J Med 382 597-2441

[9] Hegg R(2011)Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER Clin Cancer Res 17 4834-904

[10] Im Y-H(2019)Central nervous system metastasis in patients with HER2-positive metastatic breast cancer: patient characteristics, treatment, and survival from SystHERs Clin Cancer Res 25 2433-1584